A series of cardiometabolic-related news items have been observed from FDA/Novo Nordisk, Beta Bionics, Insulet, and Zealand Pharma. Below, FENIX provides highlights and insights for the respective news items.
Lilly hosted its Q3 ’24 earnings call (press release; slides) and provided updates across its CVRM portfolio. Of note, Lilly decreased its FY2024 revenue guidance by $600M to $45.4B- $46B, primarily due to the acquired IPR&D charges incurred in Q3 as well as investments in increasing the supply of tirzepatide. Following the updated guidance, Lilly’s stock price decreased by ~8%.
A series of cardiometabolic-related news items have been observed from FDA/Lexicon, Pfizer, Novartis, Sanofi, Amgen, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Abbott and Tidepool announced a cloud-to-cloud integration partnership (view press release); Lilly initiated a retatrutide study in obesity (view CT.gov record); and Apple initiated development of a prediabetes app (view article). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Dexcom hosted its Q3 ’24 earnings call (press release; slides); the Zepbound US label has been updated to include SURMOUNT-3 and -4 data (view label); and Sanofi hosted its Q3 ’24 earnings call (press release; slides; infographic). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Viking Therapeutics, Fable Therapeutics, Luna Diabetes, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Noom partners with Waltz Health for GLP-1RA cost savings (Noom press release; Waltz press release); Seraxis initiates SR-02 islet cell therapy trial in T1DM (view CT.gov record); Madrigal Pharmaceuticals announces MAESTRO-NASH OUTCOMES enrollment completion (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Lexicon Pharmaceuticals, Viatris, Gan & Lee Pharmaceuticals, Lipocine, and Noom. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Abbott, Neurogastrx, ViCentra, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Adocia announced it filed patents for stable formulations of hormone combinations for obesity and T2DM, including a semaglutide + cagrilintide combination (view press release); Seraxis announced FDA approved its IND application for a Ph1/2 study of SR-02, an islet replacement therapy (view press release); and 89Bio, Galectin Therapeutics, and Aligos Therapeutics announced upcoming data presentations at AASLD 2024 (view 89Bio press release; view Galectin press release; view Aligos press release). Below, FENIX provides highlights and insights for the respective news items.